ISPOR 2026
Sunday, May 17 - Wednesday, May 20
ISPOR 2026 News Center
Explore the news and reporting from ISPOR 2026 in the News Center with curated stories on cutting-edge topics from the conference.
Can Global Markets Adapt to the Ripple Effects of US Pricing Policy?
2026/05/21 | The Evidence Base
ISPOR 2026 Daily Round-Ups: Insights From Day 3
2026/05/21 | The Evidence Base
Can Healthcare Systems Balance Cancer Care Costs With Access and Innovation?
2026/05/20 | The Evidence Base
ISPOR 2026 Daily Round-Ups: Insights From Day 2
2026/05/20 | The Evidence Base
The True Cost of Cancer
2026/05/20 | Navlin Daily
Can US Drug Pricing Reforms Balance Affordability with Incentives for Innovation?
2026/05/19 | The Evidence Base
ISPOR 2026 Daily Round-Ups: Insights From Day 1
2026/05/19 | The Evidence Base
Is US Pharmaceutical Policy Leading or Following?
2026/05/19 | Navlin Daily
Your Guide to ISPOR 2026 - Key Themes and Program Highlights
2026/05/15 | The Evidence Base
ISPOR 2026
HEOR at the Forefront of Policy, Access, and Value
ISPOR 2026—the Society's annual, international conference—is the largest global conference for health economics and outcomes research (HEOR).
ISPOR 2026 Daily Round-Ups: Insights From Day 3 [The Evidence Base]
Inside the Third Plenary: Can Global Markets Adapt to the Ripple Effects of US Pricing Policy? [The Evidence Base]
Strategic Integration of Generative AI in Health Economic Modeling [Navlin Daily]
RWE and Value Assessment in China [Navlin Daily]
The True Cost of Cancer [Navlin Daily]
ISPOR 2026 Daily Round Ups: Insights From Day 2 [The Evidence Base]
Inside the Second Plenary: Can Healthcare Systems Balance Cancer Care Costs with Access and Innovation? [The Evidence Base]
Investors Turn Away from MFN to Focus on China [Navlin Daily]
Recent Reforms in HTA, Pricing, & Public Procurement in LATAM [Navlin Daily]
ISPOR 2026 Daily Round-Ups: Insights From Day 1 [The Evidence Base]
Inside the First Plenary: Can US Drug Pricing Reforms Balance Affordability With Incentives for Innovation? [The Evidence Base]
Is U.S. Pharmaceutical Policy Leading or Following? [Navlin Daily]
Is Value-Based Pricing for CMS Drug Price Negotiation Mission Impossible? [Navlin Daily]
Looking Ahead to ISPOR 2026 by Rob Abbott [LinkedIn]
Your Guide to ISPOR 2026 [The Evidence Base]
Living HTA and the Shift Toward Continuous Evidence Assessment: An Interview With Seye Abogunrin and Grammati Sarri [The Evidence Base]
Perspectives from the Healthcare Economist: Does AI Spell the End of HEOR? [The Evidence Base]
Themes Shaping ISPOR 2026: The Growing Relevance of HEOR as a Strategic, Future-Ready Function [The Evidence Base]
Themes Shaping ISPOR 2026: Making Patient-Centered Evidence Meaningful in Decision-Making [The Evidence Base]
Themes Shaping ISPOR 2026: From Expanding to RWD Sources to Fit-for-Purpose RWE [The Evidence Base]
Themes Shaping ISPOR 2026: Policy, Pricing, and Affordability Pressures Reshaping Access [The Evidence Base]
What to Attend at ISPOR 2026: Exploring the Conference Program with Dr Laura Pizzi [The Evidence Base]
Assessing the Return on Investment of HEOR to the Biopharmaceutical Industry [The Evidence Base]
ISPOR 2026 Plenaries and Speakers Announced [ISPOR]
ISPOR 2026 Conference Program Highlights Transformative Role of HEOR in Policy, Access, and Value [The Evidence Base]
Photo Gallery
Additional News From the Conference
Check back to view additional news stories from ISPOR 2026 that are added to the News Center as they are published.
Amplity Presents 2 Real-World Evidence Posters At ISPOR 2026 [24/7 Business Reporter]
CCS Unveils New Research at ISPOR 2026: Longitudinal Coaching and Education Sustain CGM Outcomes Beyond Initiation [Business Wire]
Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026 [Market Screener]
At ISPOR 2026, RWE Leadership Shifts Toward AI Governance [Paul Mattheneus]
Truven Launches MarketScan Partner Ecosystem to Expand Real-World Evidence Options [Merative]
Organon to Present New Research on Access and Value at ISPOR 2026 [Business Wire]
Ontada Presents 12 Real-World Research Studies at ISPOR 2026 [Business Wire]
GeneDx Showcases GeneDx Infinity™ Expansion and New Data Exploration Capabilities at ISPOR 2026 [GeneDx]
Truveta Showcases Oncology Data and AI Research Ahead of ISPOR 2026 [TipRanks, Trueta—An ISPOR Corporate Partner]
BioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 Conference [Quiver Quantitative]
Meet MarketScan at ISPOR 2026 [MarketScan]
[Video] Looking Ahead to ISPOR 2026 with Premier Applied Sciences [The Evidence Base/YouTube]
[Video]ISPOR 2026 Welcome From RTI [RTI/YouTube]
Jiao to Receive 2026 ISPOR Bernie J. O’Brien New Investigator Award at ISPOR 2026 [USCMann]
UW School of Pharmacy’s Sean Sullivan Receives ISPOR Lifetime Achievement Award [University of Washington]
Analysis Group Consultants to Present at ISPOR 2026 [Analysis Group Consultants to Present at ISPOR 2026 [Analysis Group—An ISPOR Corporate Partner]
Pistoia to Publish Guide to Pharma Firm Social Media Listening [LaboratoryNews]
Join Lumanity in Philadelphia! [Lumanity—An ISPOR Corporate Partner]
Axtria Highlights AI-Driven Outcomes Research Ahead of ISPOR 2026 [TipRanks]
Komodo Health Highlights Research Capabilities Ahead of ISPOR 2026 [TipRanks]
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% [Plus Therapeutics]
Meet the Precision AQ team at ISPOR 2026 [Precision AQ]
Certara Is Attending ISPOR 2026 [Certara]
Find Curta at ISPOR 2026 [Curta]
Model N Proud Sponsor of ISPOR 2026 [Model N]
HEOR News Desk
ISPOR's HEOR News Desk curates the latest HEOR-related news from a variety of news site around the world.
ISPOR News Webpage
Find the latest ISPOR news and announcements on the Society’s news site.
Thank You to ISPOR 2026 Media Partners:
A special thank you to the ISPOR 2026 Media Partners—The Evidence Base, Life Science Leader, Clinical Leader. Clinical Tech Leader, Journal of Medical Economics—and to all the media outlets who are reporting on the conference.
Disclaimer:
The reporting on ISPOR 2026 from external news sources reflects the views of the authors/media outlets and is not endorsed by ISPOR.